AXW-001 · Delivery platforms · Platform
Oral-dissolving solid matrix technology platform — functional no-added-sugar lollipop containing protected lactase
Industrial scale-up — Process transfer, stability and regulatory dossier.
TRL
7
Stage
Industrial scale-up
Development phase
Phase 3 — Pilot / Clinical Validation
Asset type
Platform
Valuation
Projected Indicative Valuation
US$ 3.9M – US$ 15M
- AXIOM Asset Score
- 59 / 100
- Development Phase
- Phase 3 — Pilot / Clinical Validation
- TRL
- 7
- Confidence
- Low
- Last valuation
- —
Model-based projection derived from the global size of the problem and data available in the literature, weighed against AXIOM's viability of building and delivering the solution. Indicative estimate based on the AXIOM methodology and information available as of the valuation date. It does not constitute an independent valuation, offering price, investment recommendation, or guarantee of future value.
Scientific evidence
Data under validation — publications, preprints, protocols and technical reports are published for this asset only after the source record is confirmed.
Intellectual property
Data under validation — no protection is asserted beyond documented filings. Patents, utility models, trademarks, copyright and trade secrets are listed individually once the record is confirmed.
Milestones
Milestones are registered as each evidence package is approved by the Scientific Committee. A milestone does not automatically increase valuation.